Loading...

OGEN ORAGENICS INC Other Situations 8-K Filing

RGNC

GN

ORAGENICS INC

(OGEN)

2024 8-K

Show Summary

Summary

Equity Offerings

Clinical Trial Update

Shareholder Update

Clinical Trial Update

Annual Meeting Update

Brain Health Summit

Management Update

Management Changes

Management Changes

Management Change

Investor Presentation

Investor Presentation

Stock Sale Agreement

Concussion Drug Update

Strategic Partnership

Delisting Notice

Drug Development Update

Drug Development Update

Postponement of Annual Meeting

Agreement for Public Offering

Notice of Delisting

Shareholder Director Nomina...

Appointment of Chief Clinic...

Partnership Announcement

Delisting Notice

Shareholder Director Nomina...

Appointment of Chief Medica...

Agreement for Stock Issuance

Public Offering Announcement

Management Transition

Expiration of Engagement Ag...

Clinical Trial Announcement

Termination of Agreement

Acquisition of Neurology As...

Asset Purchase Agreement

Acquisition and Appointment

Material Modifications to R...

Asset Purchase Agreement

Letter to Shareholders

Appointment of Directors

Asset Purchase Agreement

Sale and Transfer of Materi...

Termination of Lease and St...

Changes in Certifying Accou...

Equity Awards for Executive...

Private Placement

Grant for COVID-19 vaccine ...

Restatement of Financial St...

Investor Presentation

Other Special Situation

Appointment of new Chief Fi...

Commercial License Agreemen...

Agreement for Stock Sale

Regained Compliance with NY...

Reverse Stock Split

External Links:

Oragenics Inc issued a press release announcing an update on its drug development program for its lead drug candidate, ONP-002, designed to treat mild Traumatic Brain Injury (mTBI).

AI Assistant

ORAGENICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.